{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:06:37Z","timestamp":1762866397769},"reference-count":70,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2014,4,17]],"date-time":"2014-04-17T00:00:00Z","timestamp":1397692800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0092067","type":"journal-article","created":{"date-parts":[[2014,4,18]],"date-time":"2014-04-18T00:08:36Z","timestamp":1397779716000},"page":"e92067","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Impact of Inclusion of Industry Trial Results Registries as an Information Source for Systematic Reviews"],"prefix":"10.1371","volume":"9","author":[{"given":"Regine","family":"Potthast","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Verv\u00f6lgyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"McGauran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela F.","family":"Kerekes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Wieseler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,4,17]]},"reference":[{"key":"ref1","first-page":"MR000010","article-title":"Grey literature in meta-analyses of randomized trials of health care interventions","author":"S Hopewell","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMsa065779","article-title":"Selective publication of antidepressant trials and its influence on apparent efficacy","volume":"358","author":"EH Turner","year":"2008","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"c4737","DOI":"10.1136\/bmj.c4737","article-title":"Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials","volume":"341","author":"D Eyding","year":"2010","journal-title":"BMJ"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.1986.4.10.1529","article-title":"Publication bias: the case for an international registry of clinical trials","volume":"4","author":"RJ Simes","year":"1986","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.290.4.516","article-title":"Registering clinical trials","volume":"290","author":"K Dickersin","year":"2003","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/bmj.330.7497.956","article-title":"Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1)","volume":"330","author":"K Krleza-Jeric","year":"2005","journal-title":"BMJ"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMe048225","article-title":"Clinical trial registration: a statement from the International Committee of Medical Journal Editors","volume":"351","author":"C De Angelis","year":"2004","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/bmj.39233.510810.80","article-title":"Clinical trial registration","volume":"334","author":"C Laine","year":"2007","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/S0140-6736(06)68708-4","article-title":"Clinical trial registration: transparency is the watchword","volume":"367","author":"I Sim","year":"2006","journal-title":"Lancet"},{"key":"ref10","unstructured":"United States Congress (2007) Food and Drug Administration Amendments Act (FDAAA) of 2007: public law no. 110\u201385. Available: http:\/\/www.gpo.gov\/fdsys\/pkg\/PLAW-110publ85\/pdf\/PLAW-110publ85.pdf<\/ext-link>. Accessed 4 September 2013."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/bmj.39469.465139.80","article-title":"Mandatory disclosure of trial results for drugs and devices","volume":"336","author":"T Groves","year":"2008","journal-title":"BMJ"},{"key":"ref12","unstructured":"European Agency for the Evaluation of Medicinal Products (2004) EMEA launches EudraCT database. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Press_release\/2009\/11\/WC500015292.pdf<\/ext-link>. Accessed 4 September 2013."},{"key":"ref13","unstructured":"European Medicines Agency (2013) EudraCT: European Union Drug Regulating Authorities Clinical Trials [Website]. Available: https:\/\/eudract.ema.europa.eu\/<\/ext-link>. Accessed 6 Aug 2013."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1745-6215-11-37","article-title":"Reporting bias in medical research: a narrative review","volume":"11","author":"N McGauran","year":"2010","journal-title":"Trials"},{"key":"ref15","unstructured":"Pharmaceutical Research and Manufacturers of America (2002) Principles on conduct of clinical trials and communication of clinical trial results."},{"key":"ref16","unstructured":"International Federation of Pharmaceutical Manufacturers and Associations (2005) Joint position on the disclosure of clinical trial information via clinical trial registries and databases."},{"key":"ref17","unstructured":"Pharmaceutical Research and Manufacturers of America (2011) Principles on the conduct of clinical trials; communication of clinical trial results. Available: http:\/\/phrma.org\/sites\/default\/files\/pdf\/042009_clinical_trial_principles_final_0.pdf<\/ext-link>. Accessed 5 September 2013."},{"key":"ref18","unstructured":"International Federation of Pharmaceutical Manufacturers and Associations (2009) Joint position on the disclosure of clinical trial information via clinical trial registries and databases. Available: http:\/\/clinicaltrials.ifpma.org\/clinicaltrials\/fileadmin\/files\/pdfs\/EN\/November_10_2009_Updated_Joint_Position_on_the_Disclosure_of_Clinical_Trial_Information_via_Clinical_Trial_Registries_and_Databases.pdf<\/ext-link>. Accessed 4 September 2013."},{"key":"ref19","unstructured":"Office of the Attorney General (2004) Settlement sets new standard for release of drug information. Available: http:\/\/www.ag.ny.gov\/press-release\/settlement-sets-new-standard-release-drug-information<\/ext-link>. Accessed 19 September 2013."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"SE Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"ref21","unstructured":"European Medicines Agency (2010) European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim: anti-diabetes medication to be taken off the market. Available: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2010\/09\/news_detail_001119.jsp&mid=WC0b01ac058004d5c1<\/ext-link>. Accessed 9 December 2013."},{"key":"ref22","unstructured":"Food and Drug Administration (2010) FDA significantly restricts access to the diabetes drug Avandia. Available: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm226956.htm<\/ext-link>. Accessed 9 December 2013."},{"key":"ref23","unstructured":"Food and Drug Administration, editor (2011) Approved drug products with therapeutic equivalence evaluations: 31st edition. Rockville: FDA."},{"key":"ref24","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1056\/NEJMsr0806582","article-title":"Progress and deficiencies in the registration of clinical trials","volume":"360","author":"AJJ Wood","year":"2009","journal-title":"N Engl J Med"},{"key":"ref25","first-page":"CD004367","article-title":"Olanzapine in long-term treatment for bipolar disorder","author":"A Cipriani","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1590\/S1516-31802008000600010","article-title":"Can sibutramine alter systemic blood pressure in obese patients? Systematic review and meta-analysis","volume":"126","author":"HP De Lemos Jr","year":"2008","journal-title":"Sao Paulo Med J"},{"key":"ref27","first-page":"CD004028","article-title":"Valproate for schizophrenia","author":"C Schwarz","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"ref28","first-page":"CD006529","article-title":"Milnacipran versus other antidepressive agents for depression","author":"A Nakagawa","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"ref29","first-page":"CD006117","article-title":"Sertraline versus other antidepressive agents for depression","author":"A Cipriani","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"ref30","first-page":"iii, xi","article-title":"Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation","volume":"12","author":"R Ara","year":"2008","journal-title":"Health Technol Assess"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"d8141","DOI":"10.1136\/bmj.d8141","article-title":"Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications","volume":"344","author":"B Wieseler","year":"2012","journal-title":"BMJ"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e1001526","DOI":"10.1371\/journal.pmed.1001526","article-title":"Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data","volume":"10","author":"B Wieseler","year":"2013","journal-title":"PLoS Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1745-6215-10-56","article-title":"Compliance of clinical trial registries with the World Health Organization minimum data set: a survey","volume":"10","author":"LP Moja","year":"2009","journal-title":"Trials"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"f6104","DOI":"10.1136\/bmj.f6104","article-title":"Non-publication of large randomized clinical trials: cross sectional analysis","volume":"347","author":"CW Jones","year":"2013","journal-title":"BMJ"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.322.5898.44c","article-title":"Closing a loophole in the FDA Amendments Act","volume":"322","author":"EH Turner","year":"2008","journal-title":"Science"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"f4219","DOI":"10.1136\/bmj.f4219","article-title":"Deaths in trials should always be reported","volume":"347","author":"J Schroll","year":"2013","journal-title":"BMJ"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e3081","DOI":"10.1371\/journal.pone.0003081","article-title":"Systematic review of the empirical evidence of study publication bias and outcome reporting bias","volume":"3","author":"K Dwan","year":"2008","journal-title":"PLoS One"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/bmj.38356.424606.8F","article-title":"Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors","volume":"330","author":"AW Chan","year":"2005","journal-title":"BMJ"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/bmj.326.7400.1171","article-title":"Evidence b(i)ased medicine: selective reporting from studies sponsored by pharmaceutical industry; review of studies in new drug applications","volume":"326","author":"H Melander","year":"2003","journal-title":"BMJ"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMsa0906126","article-title":"Outcome reporting in industry-sponsored trials of gabapentin for off-label use","volume":"361","author":"SS Vedula","year":"2009","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1745-6215-10-116","article-title":"Association of trial registration with the results and conclusions of published trials of new oncology drugs","volume":"10","author":"N Rasmussen","year":"2009","journal-title":"Trials"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/bmj.38973.444699.0B","article-title":"Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review","volume":"333","author":"AW Jorgensen","year":"2006","journal-title":"BMJ"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/bmj.326.7400.1167","article-title":"Pharmaceutical industry sponsorship and research outcome and quality: systematic review","volume":"326","author":"J Lexchin","year":"2003","journal-title":"BMJ"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1001\/jama.289.4.454","article-title":"Scope and impact of financial conflicts of interest in biomedical research: a systematic review","volume":"289","author":"JE Bekelman","year":"2003","journal-title":"JAMA"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"e1000144","DOI":"10.1371\/journal.pmed.1000144","article-title":"Trial publication after registration in clinicaltrials.gov: a cross-sectional analysis","volume":"6","author":"JS Ross","year":"2009","journal-title":"PLoS Med"},{"key":"ref46","unstructured":"Veitch E (2012) Silent takedown of the pharma trials database\u2026and more. In: PLOS Blogs. Available: http:\/\/blogs.plos.org\/speakingofmedicine\/2012\/03\/23\/silent-takedown-of-the-pharma-trials-database%E2%80%A6and-more\/<\/ext-link>. Accessed 8 August 2013."},{"key":"ref47","unstructured":"European Medicines Agency (2010) European Medicines Agency widens public access to documents: policy on access to documents also sets out new approach for proactive disclosure of documents. Available: www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2010\/11\/news_detail_001158.jsp&mid=WC0b01ac058004d5c1&murl=menus\/news_and_events\/news_and_events.jsp<\/ext-link>. Accessed 9 December 2013."},{"key":"ref48","unstructured":"European Medicines Agency (2013) Draft policy 70: publication and access to clinical-trial data. Available: http:\/\/www.emea.europa.eu\/ema\/index.jsp?curl=pages\/includes\/document\/document_detail.jsp?webContentId=WC500144730&mid=WC0b01ac058009a3dc<\/ext-link>. Accessed 1 July 2013."},{"key":"ref49","article-title":"Pharma group sues European regulator over data","author":"A Jack","year":"2013","journal-title":"Financial Times"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1371\/journal.pmed.0040078","article-title":"Epidemiology and reporting characteristics of systematic reviews","volume":"4","author":"D Moher","year":"2007","journal-title":"PLoS Med"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Lefebvre C, Manheimer E, Glanville J (2008) Searching for studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. New York: Wiley. pp. 95\u2013150.","DOI":"10.1002\/9780470712184.ch6"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"e42812","DOI":"10.1371\/journal.pone.0042812","article-title":"Identification of additional trials in prospective trial registers for Cochrane systematic reviews","volume":"7","author":"WA van Enst","year":"2012","journal-title":"PLoS One"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"f2231","DOI":"10.1136\/bmj.f2231","article-title":"Searching for unpublished data for Cochrane reviews: cross sectional study","volume":"346","author":"JB Schroll","year":"2013","journal-title":"BMJ"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"A Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"ref55","unstructured":"Abbott Laboratories A randomized, double-blind study of the safety and efficacy of Depakote ER plus an atypical antipsychotic vs. an atypical antipsychotic alone in the treatment of schizophrenia: clinical study report M02-547. In: ClinicalStudyResults.org<\/ext-link>. Available: http:\/\/www.clinicalstudyresults.org\/documents\/company-study_782_0.pdf<\/ext-link>. Accessed 4 October 2009 (no longer available). Now available: http:\/\/www.abbott.com\/static\/cms_workspace\/content\/document\/Citizenship\/clinical_study_results\/divalproex-sodium_M02-547-study.pdf<\/ext-link>. Accessed 25 November 2013."},{"key":"ref56","unstructured":"Abbott Laboratories (2006) Blood pressure and weight trajectory on a dual antihypertensive combination plus sibutramine versus placebo in obese hypertensives: clinical study report KD 200010. In: ClinicalStudyResults.org<\/ext-link>. Available: http:\/\/www.clinicalstudyresults.org\/documents\/company-study_1275_0.pdf<\/ext-link>. Accessed 24 February 2010 (no longer available). Now available: http:\/\/www.abbott.com\/static\/cms_workspace\/content\/document\/Citizenship\/clinical_study_results\/sibutramine_kd200010-study.pdf<\/ext-link> Accessed 25 November 2013."},{"key":"ref57","unstructured":"Abbott Laboratories (2006) Randomized trial of obese non-diabetic Malaysians using sibutramine: a randomized double-blind placebo-controlled study of sibutramine in the management of obese subjects in Malaysia; clinical trial report MLAY02001. In: ClinicalStudyResults.org<\/ext-link>. Available: http:\/\/www.clinicalstudyresults.org\/documents\/company-study_4130_0.pdf<\/ext-link>. Accessed 24 February 2010 (no longer available). Now available: http:\/\/www.abbott.com\/static\/cms_workspace\/content\/document\/Citizenship\/clinical_study_results\/sibutramine_mlay-02-001-study.pdf<\/ext-link>. Accessed 25 November 2013."},{"key":"ref58","unstructured":"Abbott Laboratories A multicenter, double-blind, randomized, placebo-controlled, parallel group study to examine the longer-term efficacy and safety of Meridia (sibutramine hydrochloride) in obese subjects; clinical study report SB118. In: ClinicalStudyResults.org<\/ext-link>. Available: http:\/\/www.clinicalstudyresults.org\/documents\/company-study_1146_0.pdf<\/ext-link>. Accessed 24 February 2010 (no longer available). Now available: http:\/\/www.abbott.com\/static\/cms_workspace\/content\/document\/Citizenship\/clinical_study_results\/sibutramine_sb118-study.pdf<\/ext-link>. Accessed 25 November 2013."},{"key":"ref59","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/0003-4819-145-2-200607180-00005","article-title":"Effects of sibutramine treatment in obese adolescents: a randomized trial","volume":"145","author":"RI Berkowitz","year":"2006","journal-title":"Ann Intern Med"},{"key":"ref60","unstructured":"Eli Lilly (2004) Olanzapine added to mood stabilizer for relapse prevention in patients with bipolar disorder: CT registry ID#1035b. In: ClinicalStudyResults.org<\/ext-link>. Available: http:\/\/www.clinicalstudyresults.org\/documents\/company-study_173_0.pdf<\/ext-link>. Accessed 13 April 2009 (no longer available). Now available: http:\/\/www.lillytrials.com\/results\/Zyprexa.pdf<\/ext-link>. Accessed 25 November 2013."},{"key":"ref61","unstructured":"Eli Lilly (2004) Olanzapine versus placebo in the prevention of relapse in bipolar disorder: clinical study summary; study F1D-MC-HGHL. In: ClinicalStudyResults.org<\/ext-link>. Available: http:\/\/www.clinicalstudyresults.org\/documents\/company-study_1164_0.pdf<\/ext-link> Accessed 13 April 2009 (no longer available). Now available: http:\/\/www.lillytrials.com\/results\/Zyprexa.pdf<\/ext-link>. Accessed 25 November 2013."},{"key":"ref62","unstructured":"Eli Lilly (2004) Olanzapine versus divalproex in the treatment of acute mania: clinical study summary; study F1D-US-HGHQ. In: ClinicalStudyResults.org<\/ext-link>. Available: http:\/\/www.clinicalstudyresults.org\/documents\/company-study_176_0.pdf<\/ext-link>. Accessed 13 April 2009 (no longer available). Now available: http:\/\/www.lillytrials.com\/results\/Zyprexa.pdf<\/ext-link>. Accessed 25 November 2013."},{"key":"ref63","unstructured":"Eli Lilly (2004) Olanzapine versus lithium in relapse prevention in bipolar disorder: clinical study summary; study F1D-MC-HGHT. In: ClinicalStudyResults.org<\/ext-link>. Available: http:\/\/www.clinicalstudyresults.org\/documents\/company-study_603_0.pdf<\/ext-link>. Accessed 13 April 2009 (no longer available). Now available: http:\/\/www.lillytrials.com\/results\/Zyprexa.pdf<\/ext-link>. Accessed 25 November 2013."},{"key":"ref64","unstructured":"Wyeth (2006) A multicenter, double-blind comparative study to administer venlafaxine ER (18.75 mg\/day), venlafaxine ER (75 to 150 mg\/day) or milnacipran hydrochloride (50 to 100 mg\/day) for 12 weeks to patients with major depressive disorder to demonstrate non-inferiority of venlafaxine ER (75 to 150 mg\/day) to milnacipran hydrochloride in antidepressive effect based on the HAM-D17<\/sub> response rate: protocol 0600B1-816. In: ClinicalStudyResults.org<\/ext-link>. Available: http:\/\/www.clinicalstudyresults.org\/documents\/company-study_9750_1.pdf<\/ext-link>. Accessed 20 February 2010 (no longer available)."},{"key":"ref65","unstructured":"Pfizer (2008) Sertraline\/[S,S]-reboxetine combination versus sertraline and [S,S]-reboxetine monotherapy in major depressive disorder (MDD) in a double-blind, placebo-controlled, eight week study: protocol no. A0501075. In: ClinicalStudyResults.org<\/ext-link>. Available: www.clinicalstudyresults.org<\/ext-link>. Accessed 20 February 2010 (no longer available)."},{"key":"ref66","unstructured":"Pfizer (2008) A multicenter randomized, double-blind, parallel-group study of sertraline versus venlafaxine XR in the acute treatment of outpatients with major depressive disorder. In: Clinical Study Results Database. Available: www.clinicalstudyresults.org<\/ext-link>. Accessed 20 February 2010 (no longer available)."},{"key":"ref67","unstructured":"Glaxo Smith Kline (2005) A multicenter, double-blind, placebo-controlled comparison of the effects on sexual functioning of wellbutrin (bupropion HCI) sustained release and sertraline in outpatients with moderate to severe recurrent major depression (WELL AK1A4001). In: Clinical Study Results Database. Available: www.clinicalstudyresults.org<\/ext-link> Accessed 20 February 2010 (no longer available)."},{"key":"ref68","unstructured":"Glaxo Smith Kline (2005) A multicenter, double-blind, placebo-controlled comparison of the effects on sexual functioning of wellbutrin (bupropion HCl) sustained release and sertraline in outpatients with moderate to severe recurrent major depression (WELL AK1A4002). In: Clinical Study Results Database. Available: www.clinicalstudyresults.org<\/ext-link> Accessed 20 February 2010 (no longer available)."},{"key":"ref69","unstructured":"Glaxo Smith Kline (2005) The safety and efficacy of wellbutrin sustained release and sertraline in depressed outpatients. In: Clinical Study Results Database. Available: www.clinicalstudyresults.org<\/ext-link> Accessed 20 February 2010 (no longer available)."},{"key":"ref70","unstructured":"Merck (2005) A multicenter, double-blind, randomized study to evaluate the lipid-altering efficacy, safety, and tolerability of ezetimibe coadministered with simvastatin versus simvastatin monotherapy in African-American subjects with primary hypercholesterolemia (protocol no. P03377). In: ClinicalStudyResults.org<\/ext-link>. Available: www.clinicalstudyresults.org<\/ext-link>. Accessed 10 July 2011 (no longer available)."}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0092067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:44:23Z","timestamp":1588970663000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0092067"}},"subtitle":[],"editor":[{"given":"Roberta W.","family":"Scherer","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,4,17]]},"references-count":70,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,4,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0092067","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,17]]}}}